| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.095 | 0.06 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | -0.067 | 0.06 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | -0.095 | 0.06 |
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | -0.068 | 0.06 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | -0.19 | 0.06 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.069 | 0.06 |
| mRNA | Ko-143 | CTRPv2 | pan-cancer | AAC | -0.066 | 0.07 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | 0.061 | 0.07 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | -0.088 | 0.07 |
| mRNA | navitoclax:PLX-4032 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.062 | 0.07 |